Methyldopa
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
| |
| Methyldopa
| |
| Systematic (IUPAC) name | |
| 2-amino-3-(3,4-dihydroxyphenyl)-2-methyl-propanoic acid | |
| Identifiers | |
| CAS number | |
| ATC code | C02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C10H13NO4 |
| Mol. mass | 211.215 g/mol |
| Pharmacokinetic data | |
| Bioavailability | approximately 50% |
| Metabolism | Hepatic |
| Half life | 105 minutes |
| Excretion | Renal for metabolites |
| Therapeutic considerations | |
| Pregnancy cat. |
a drug of choice in PIH |
| Legal status |
℞ Prescription only |
| Routes | Oral, IV |
|
WikiDoc Resources for Methyldopa | |
|
Articles | |
|---|---|
|
Most recent articles on Methyldopa | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Methyldopa at Clinical Trials.gov Clinical Trials on Methyldopa at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Methyldopa
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Methyldopa Discussion groups on Methyldopa Patient Handouts on Methyldopa Directions to Hospitals Treating Methyldopa Risk calculators and risk factors for Methyldopa
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Methyldopa | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Methyldopa or alpha-methyldopa (brand names Aldomet®, Apo-Methyldopa®, Dopamet®, Novomedopa®) is a centrally-acting adrenergic antihypertensive medication. Its use is now deprecated following introduction of alternative safer classes of agents. However it continues to have a role in otherwise difficult to treat hypertension and pregnancy-induced hypertension.
Mechanism of action
Methyldopa has variable absorption from the gut of approximately 50%. It is metabolized in the intestines and liver; its metabolite alpha-methylnorepineprine acts in the brain to stimulate alpha-adrenergic receptors decreasing total peripheral resistance. It is excreted in urine.
Methyldopa, in its active metabolite form, leads to increased alpha-2 receptor-mediated inhibition of SNS (centrally and peripherally), allowing PSNS tone to increase. Such activity leads to a decrease in total peripheral resistance (TPR) and cardiac output.
If methyldopa is abruptly withdrawn, rebound hypertension happens. This results because the long term use of methyldopa lowers the sensitivity of presynaptic alpha 2 receptors: the release of norepinephrine (NE) from sympathetic nerve endings is modulated by NE itself acting on the presynaptic alpha 2 autoreceptors thus inhibiting its own release. The discontinuation of methyldopa removes the inhibition on NE release leading to excessive NE release from the SNS and the rebound hypertension.
History
When introduced it was a mainstay of antihypertensive therapy, but its use has declined, with increased use of other safer classes of agents. One of its important present-day uses is in the management of pregnancy-induced hypertension, as it is relatively safe in pregnancy compared to other antihypertensive drugs.
Side effects
There are many possible reported side-effects with some, whilst rare, being serious. Side effects are usually fewer if the dose is less than 1 g per day:[1]
- Gastro-intestinal disturbances
- Dry mouth
- Bradycardia (slow pulse rate)
- Worsening of angina
- Orthostatic hypotension (Postural hypotension)
- Sedation, headaches, dizziness
- Myalgia (muscle pain), arthralgia (joint pain) or paraesthesia (numbness)
- Nightmares, mild psychosis, depression
- Parkinsonism
- Bell's palsy
- Abnormal liver functions tests and hepatitis
- Pancreatitis
- Haemolytic anaemia
- Bone marrow suppresion leading to thrombocytopenia (low platelets) or leucopenia (low white blood cells)
- Hypersensitivity reactions including lupus erythematosus-like syndrome, myocarditis (heart muscle inflammation), pericarditis and rashes
- Ejaculatory failure, Impotence, decreased libido, gynecomastia (breast enlargement in men), hyperprolactinaemia and amenorrhoea
- Note that if used in pregnant women, it may cause a positive Coombs test
Footnotes
de:Methyldopa hr:Metildopasv:Metyldopa
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
